A Safety and Tolerability Study of ILB in Patients With Amyothrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2021-07-28
Target enrollment:
Participant gender:
Summary
This is a phase II study to determine the safety and tolerability of ILB , a type of low
molecular weight dextran sulfate, in patients with Motor Neurone Disease (MND)/ Amyotrophic
Lateral Sclerosis (ALS)
Phase:
Phase 2
Details
Lead Sponsor:
University of Birmingham
Collaborators:
Neuregenix TikoMed AB University Hospital Birmingham